A Respiratory Syncytial Virus (RSV) Prefusion F Candidate Vaccine (RSVPreF3 OA) is Efficacious in Adults 60 Years of Age ( YOA)

M. Ison,A. Papi,J. Langley,D. Lee,I Leroux-Roels,F. Martinon-Torres,T. Schwarz,R. van Zyl-Smit, N. Dezutter, N. de Schrevel, L. Fissette,M. David,M. Van Der Wielen,L. Kostanyan, V Hulstrom

PNEUMOLOGIE（2023）

引用 0|浏览4

暂无评分

摘要

Background RSV-associated acute respiratory infections (ARI), particularly lower respiratory tract diseases (LRTD), present a significant disease burden in older adults. Currently, there are no approved vaccines against RSV. We present results from an ongoing study designed to demonstrate the vaccine efficacy (VE) of the AS01E-adjuvanted RSVPreF3 OA in adults≥60 YOA.

查看译文

关键词

respiratory syncytial virus,rsvpref3 oa

AI 理解论文

溯源树

样例

生成溯源树，研究论文发展脉络

Chat Paper

正在生成论文摘要